Skip to main content
. 2022 Sep 5;2022:6911246. doi: 10.1155/2022/6911246

Figure 2.

Figure 2

The process for MM response prediction of bortezomib, cyclophosphamide, and dexamethasone (BCD) and bortezomib, lenalidomide, and dexamethasone (VRD).